ARK Investment Management LLC Has $22.92 Million Stock Holdings in COMPASS Pathways plc (NASDAQ:CMPS)

ARK Investment Management LLC grew its position in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 7.6% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,618,871 shares of the company’s stock after buying an additional 186,040 shares during the quarter. ARK Investment Management LLC’s holdings in COMPASS Pathways were worth $22,915,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. LPL Financial LLC grew its stake in COMPASS Pathways by 7.6% during the second quarter. LPL Financial LLC now owns 11,055 shares of the company’s stock worth $120,000 after buying an additional 782 shares during the last quarter. Raymond James & Associates grew its stake in COMPASS Pathways by 4.1% during the first quarter. Raymond James & Associates now owns 34,435 shares of the company’s stock worth $444,000 after buying an additional 1,341 shares during the last quarter. TAP Consulting LLC grew its stake in COMPASS Pathways by 14.7% during the third quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock worth $95,000 after buying an additional 1,645 shares during the last quarter. UBS Group AG grew its stake in COMPASS Pathways by 46.6% during the first quarter. UBS Group AG now owns 6,289 shares of the company’s stock worth $62,000 after buying an additional 1,998 shares during the last quarter. Finally, Quantbot Technologies LP grew its stake in COMPASS Pathways by 156.8% during the first quarter. Quantbot Technologies LP now owns 3,338 shares of the company’s stock worth $43,000 after buying an additional 2,038 shares during the last quarter. 46.19% of the stock is owned by institutional investors.

COMPASS Pathways Price Performance

CMPS opened at $9.50 on Thursday. COMPASS Pathways plc has a one year low of $5.01 and a one year high of $12.75. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.33 and a quick ratio of 13.33. The company’s 50 day simple moving average is $10.34 and its 200-day simple moving average is $8.28. The stock has a market capitalization of $588.46 million, a P/E ratio of -3.97 and a beta of 2.52.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). Sell-side analysts anticipate that COMPASS Pathways plc will post -2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of COMPASS Pathways in a research note on Tuesday, December 12th. They set a “buy” rating and a $16.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $120.00 price target on shares of COMPASS Pathways in a research note on Friday, March 1st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $49.00.

Insider Buying and Selling at COMPASS Pathways

In other COMPASS Pathways news, Director George Jay Goldsmith sold 25,750 shares of the firm’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $8.35, for a total value of $215,012.50. Following the transaction, the director now directly owns 4,172,404 shares of the company’s stock, valued at $34,839,573.40. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other COMPASS Pathways news, Director George Jay Goldsmith sold 25,750 shares of the stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $8.35, for a total value of $215,012.50. Following the sale, the director now directly owns 4,172,404 shares in the company, valued at $34,839,573.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ekaterina Malievskaia sold 17,765 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $10.45, for a total transaction of $185,644.25. Following the completion of the sale, the director now owns 4,092,573 shares in the company, valued at $42,767,387.85. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 111,175 shares of company stock valued at $1,058,199. 23.99% of the stock is currently owned by insiders.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.